1. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease [published online ahead of print May 2];Blennow;Alzheimers Dement,2014
2. Longitudinal change in CSF tau and Aβ biomarkers for up to 48 months in ADNI;Toledo;Acta Neuropathol,2013
3. US FDA and personalized medicine: In vitro diagnostic regulatory perspective;Tevak;Per Med,2010
4. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”[Erratum in: Neurobiol Aging May-Jun;19(3):285];Neurobiol Aging,1998
5. Clinical features and multidisciplinary approaches to dementia care;Grand;J Multidiscip Health,2011